Related Experiment Video

Updated: Aug 14, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Biography as the Missing Variable in Drug Development: A Case for Bio-Biographical Mechanistic Profiling

Ralph I Horwitz1

  • 1Temple University, Philadelphia, Pennsylvania, USA.

Clinical Pharmacology and Therapeutics
|August 13, 2026
PubMed

Insights

Biographical factors like stress and trauma significantly impact treatment response by altering biological pathways. Measuring these biographical elements alongside biomarkers can improve patient stratification for therapies like immune checkpoint inhibitors.

Area of Science:

  • Oncology
  • Immunology
  • Psychoneuroimmunology

Background:

  • Clinical trial failures often stem from unmeasured biological heterogeneity.
  • Biographical factors (stress, trauma, social isolation) represent a neglected source of heterogeneity.
  • These biographical elements operate via molecular pathways targeted by modern therapeutics.

Purpose of the Study:

  • To introduce Bio-biographical mechanistic profiling (BBMP) as a method to measure biographical influences on drug pathways.
  • To identify patients whose treatment pathway engagement is modified by biographical factors.
  • To bridge the gap between pathway-matched treatment and personalized medicine.

Main Methods:

  • Prospective, mechanism-matched measurement of biographical factors and standard biomarkers.
  • Utilizing existing data from non-small cell lung cancer and melanoma studies.
  • Assessing immunological intermediaries linking biographical measurement to treatment response.

Main Results:

  • Pretreatment biographical measurement predicts immune checkpoint inhibitor response in cancer patients.
  • Demonstrated that the biography-heterogeneity axis is both detectable and pharmacologically relevant.
  • Established proof of concept for BBMP's ability to identify modified biological pathways.

Conclusions:

  • Biographical factors are crucial, measurable contributors to patient heterogeneity in clinical trials.
  • BBMP offers a novel approach to personalize cancer treatment by accounting for life experiences.
  • Integrating biographical data can enhance the efficacy of targeted therapies, particularly immune checkpoint inhibitors.

More Related Videos

A Protocol For Uncovering Neural Mechanisms Of Neurotherapeutic Effects On Electroencephalography Using The Human Neocortical Neurosolver07:47

A Protocol For Uncovering Neural Mechanisms Of Neurotherapeutic Effects On Electroencephalography Using The Human Neocortical Neurosolver

Published on: May 19, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

Related Concept Videos

Measurement of Bioavailability: Pharmacodynamic Methods01:20

Measurement of Bioavailability: Pharmacodynamic Methods

Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
Mechanistic Models: Overview of Compartment Models01:21

Mechanistic Models: Overview of Compartment Models

Mechanistic models, a category encompassing both physiological and compartmental modeling, differ from empirical models' approaches to incorporating known factors about the systems being modeled. Empirical models describe data with minimal assumptions, while mechanistic models aim to provide a robust description of available data by specifying assumptions and integrating known factors about the system. Compartmental analysis is a key example of a mechanistic model in pharmacokinetics and...
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the appropriate...
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least squares (OLS)...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .